JP2015509110A5 - - Google Patents

Download PDF

Info

Publication number
JP2015509110A5
JP2015509110A5 JP2014555351A JP2014555351A JP2015509110A5 JP 2015509110 A5 JP2015509110 A5 JP 2015509110A5 JP 2014555351 A JP2014555351 A JP 2014555351A JP 2014555351 A JP2014555351 A JP 2014555351A JP 2015509110 A5 JP2015509110 A5 JP 2015509110A5
Authority
JP
Japan
Prior art keywords
tautomer
compound
pharmaceutically acceptable
alkyl
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014555351A
Other languages
English (en)
Japanese (ja)
Other versions
JP6002785B2 (ja
JP2015509110A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2013/050555 external-priority patent/WO2013114250A1/en
Publication of JP2015509110A publication Critical patent/JP2015509110A/ja
Publication of JP2015509110A5 publication Critical patent/JP2015509110A5/ja
Application granted granted Critical
Publication of JP6002785B2 publication Critical patent/JP6002785B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014555351A 2012-02-03 2013-01-22 ナトリウムチャネルモジュレーターとしてのベンゾイミダゾールおよびイミダゾピリジン誘導体 Expired - Fee Related JP6002785B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261594460P 2012-02-03 2012-02-03
US61/594,460 2012-02-03
PCT/IB2013/050555 WO2013114250A1 (en) 2012-02-03 2013-01-22 Benziimidazole and imidazopyridine derivatives as sodium channel modulators

Publications (3)

Publication Number Publication Date
JP2015509110A JP2015509110A (ja) 2015-03-26
JP2015509110A5 true JP2015509110A5 (enExample) 2016-02-12
JP6002785B2 JP6002785B2 (ja) 2016-10-05

Family

ID=47846092

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014555351A Expired - Fee Related JP6002785B2 (ja) 2012-02-03 2013-01-22 ナトリウムチャネルモジュレーターとしてのベンゾイミダゾールおよびイミダゾピリジン誘導体

Country Status (9)

Country Link
US (1) US8927587B2 (enExample)
EP (1) EP2809655B1 (enExample)
JP (1) JP6002785B2 (enExample)
AR (1) AR089865A1 (enExample)
CA (1) CA2861439C (enExample)
ES (1) ES2548228T3 (enExample)
TW (1) TW201341370A (enExample)
UY (1) UY34602A (enExample)
WO (1) WO2013114250A1 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10208023B2 (en) 2013-03-01 2019-02-19 Mark G. DeGiacomo Heterocyclic inhibitors of the sodium channel
LT3080134T (lt) 2013-12-13 2018-11-12 Vertex Pharmaceuticals Incorporated Piridono amidų provaistai, naudotini kaip natrio kanalų moduliatoriai
EP3110799A4 (en) * 2014-02-27 2017-10-11 Epirus Biopharmaceuticals, Inc. Heterocyclic inhibitors of the sodium channel
JP2017516803A (ja) 2014-05-30 2017-06-22 ファイザー・インク ナトリウムチャネル阻害剤として有用なベンゼンスルホンアミド
WO2016009303A1 (en) 2014-07-17 2016-01-21 Pfizer Inc. Pharmaceutical combinations comprising gabapentin or pregabalin with nav1.7 inhibitors
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10407395B2 (en) * 2015-09-11 2019-09-10 Sumitomo Dainippon Pharma Co., Ltd. Benzimidazole compound and medical use thereof
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US11358977B2 (en) 2017-05-16 2022-06-14 Vertex Pharmaceuticals Incorporated Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels
JPWO2018212162A1 (ja) * 2017-05-17 2020-03-19 株式会社トクヤマ ジアミノベンゼン化合物の製造方法
ES3008911T3 (en) 2017-07-11 2025-03-25 Vertex Pharma Carboxamides as modulators of sodium channels
ES2963417T3 (es) * 2018-01-15 2024-03-27 UCB Biopharma SRL Derivados de imidazol condensados como moduladores de IL-17
US20190343817A1 (en) 2018-02-12 2019-11-14 Vertex Pharmaceuticals Incorporated Method of treating pain
WO2020146682A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
WO2020146612A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
WO2020176763A1 (en) 2019-02-27 2020-09-03 Vertex Pharmaceuticals Incorporated Dosage form comprising prodrug of na 1.8 sodium channel inhibitor
WO2020219867A1 (en) 2019-04-25 2020-10-29 Vertex Pharmaceuticals Incorporated Pyridone amide co-crystal compositions for the treatment of pain
CR20220316A (es) 2019-12-06 2022-10-07 Vertex Pharma Tetrahidrofuranos sustituidos como moduladores de canales de sodio
EP4136089A4 (en) * 2020-04-14 2024-05-29 The Trustees of The University of Pennsylvania SUBSTITUTED {1,2,4,} TRIAZOLO{1,5-A} PYRIMIDINE COMPOUNDS AND THEIR USE IN THE STABILIZATION OF MICROTUBULES
WO2022108849A1 (en) * 2020-11-17 2022-05-27 Arisan Therapeutics Inc. Heterocyclic compounds as therapeutic agents
JP2024522292A (ja) 2021-06-04 2024-06-13 バーテックス ファーマシューティカルズ インコーポレイテッド ナトリウムチャネルのモジュレーターとしてのn-(ヒドロキシアルキル(ヘテロ)アリール)テトラヒドロフランカルボキサミド
BR112023025264A2 (pt) 2021-06-04 2024-02-20 Vertex Pharma Formas farmacêuticas sólidas e regimes posológicos compreendendo (2r,3s,4s,5r)-4-[[3- (3,4-difluoro-2-metóxi-fenil)-4,5-dimetil-5-(trifluorometil) tetra-hidrofuran-2-carbonil]amino ]piridina-2-carboxamida
AU2022285758A1 (en) 2021-06-04 2023-11-30 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran analogs as modulators of sodium channels
CN117858875A (zh) 2021-06-04 2024-04-09 沃泰克斯药物股份有限公司 羟基和(卤代)烷氧基取代的四氢呋喃作为钠通道调节剂
CN117813302A (zh) 2021-06-04 2024-04-02 沃泰克斯药物股份有限公司 经取代的四氢呋喃-2-甲酰胺作为钠通道调节剂
CN117794919A (zh) 2021-06-04 2024-03-29 沃泰克斯药物股份有限公司 N-(羟烷基(杂)芳基)四氢呋喃甲酰胺类似物作为钠通道调节剂
CN114249654B (zh) * 2021-12-30 2023-11-14 江苏广域化学有限公司 烷基苯胺类化合物的制备方法
CN116462662A (zh) 2022-01-18 2023-07-21 成都康弘药业集团股份有限公司 芳香并环类Nav1.8抑制剂及其用途
CN114288289A (zh) * 2022-02-17 2022-04-08 昆山彭济凯丰生物科技有限公司 具有镇痛和/或止痒功能的药物组合物及其应用
EP4511117A1 (en) 2022-04-22 2025-02-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
JP2025513454A (ja) 2022-04-22 2025-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の治療のためのヘテロアリール化合物
TW202408501A (zh) 2022-04-22 2024-03-01 美商維泰克斯製藥公司 用於治療疼痛之雜芳基化合物
PE20251179A1 (es) 2022-04-22 2025-04-23 Vertex Pharma Compuestos de heteroarilo para el tratamiento del dolor
JP2025516005A (ja) 2022-04-25 2025-05-23 サイトワン セラピューティクス インコーポレイテッド 疼痛の処置のためのnav1.8の二環式複素環アミド阻害剤
KR20250120351A (ko) 2022-12-06 2025-08-08 버텍스 파마슈티칼스 인코포레이티드 나트륨 채널의 치환된 테트라하이드로푸란 조절제의 합성을 위한 방법
CN116621789A (zh) * 2023-05-31 2023-08-22 上海吉奉生物科技有限公司 一种(4s)-3-[2-[[芴甲氧羰基]氨基]乙酰基]-2,2-二甲基-4-恶唑烷羧酸的合成方法
WO2025090465A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2025090480A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2025090516A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Methods of preparing compounds for treating pain and solid forms thereof
TW202535867A (zh) 2023-10-23 2025-09-16 美商維泰克斯製藥公司 用於治療疼痛之鈉通道調節劑及其固體形式的製備方法
US20250186419A1 (en) 2023-12-07 2025-06-12 Vertex Pharmaceuticals Incorporated Dosing regimens for treating pain
WO2025160286A1 (en) 2024-01-24 2025-07-31 Siteone Therapeutics, Inc. 2-aryl cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8604566D0 (sv) * 1986-10-27 1986-10-27 Haessle Ab Novel compunds
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
AU2001296799A1 (en) * 2000-10-06 2002-04-15 Neurogen Corporation Benzimidazole and indole derivatives as crf receptor modulators
EP1532119A2 (en) * 2002-07-31 2005-05-25 Euro-Celtique S.A. Aryl substituted benzimidazoles and their use as sodium channel blockers
JP4800216B2 (ja) * 2003-10-24 2011-10-26 エグゼリクシス, インコーポレイテッド p70S6キナーゼモジュレーターおよび使用方法
WO2005113580A1 (en) 2004-05-21 2005-12-01 Pfizer Inc. Anticoronviral compounds and compositions, their pharmaceutical uses and materials for their synthesis
MX2008011968A (es) * 2006-03-31 2008-10-01 Astrazeneca Ab Compuestos biciclicos de bencimidazol y su uso como potenciadores del receptor metabotropico de glutamato.
GEP20125425B (en) 2006-10-18 2012-03-26 Pfizer Prod Inc Biaryl ether urea compounds
US20080207683A1 (en) * 2007-02-15 2008-08-28 Darin Allen Biaryl-substituted tetrahydro-pyrazolo-pyridine modulators of cathepsin s
CL2008000835A1 (es) 2007-03-23 2008-10-03 Icagen Inc Pfizer Ltd Compuestos derivados de sulfonamidas, inhibidores de los canales de calcio; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor, sindrome de intestino irritable, enfermedad de crohn, taquiarritm
AP2516A (en) 2007-05-03 2012-11-26 Pfizer Ltd 2-Pyridine carboxamide derivatives as sodium channel modulators
US20100227872A1 (en) 2007-05-03 2010-09-09 Mark Ian Kemp Pyrazine derivatives
WO2009012242A2 (en) 2007-07-13 2009-01-22 Icagen, Inc. Sodium channel inhibitors
EP2234486A4 (en) * 2007-12-19 2011-09-14 Scripps Research Inst BENZIMIDAZOLES AND ANALOGS AS INHIBITORS OF RHO-KINASE
EP2072516A1 (en) * 2007-12-21 2009-06-24 Santhera Pharmaceuticals (Schweiz) AG Substituted imidazopyridine derivates as Melancortin-4 receptor antagonists
US8628695B2 (en) 2008-04-18 2014-01-14 E I Du Pont De Nemours And Company Surface-modified ruthenium oxide conductive material, lead-free glass(es), thick film resistor paste(s), and devices made therefrom
TW201028142A (en) * 2008-10-30 2010-08-01 Biogen Idec Inc Heterobicyclic sphingosine 1-phosphate analogs
JP5667934B2 (ja) * 2010-06-28 2015-02-12 大日本住友製薬株式会社 新規2環性複素環化合物からなる医薬
ES2786298T3 (es) 2011-03-03 2020-10-09 Zalicus Pharmaceuticals Ltd Inhibidores de benzimidazol del canal de sodio

Similar Documents

Publication Publication Date Title
JP2015509110A5 (enExample)
JP2018537413A5 (ja) 化合物、医薬的に許容される塩又はその立体異性体及び医薬組成物
JP2014506907A5 (enExample)
JP2014511891A5 (enExample)
RU2015149527A (ru) Производные доластатина 10 и ауристатинов
JP2014511892A5 (enExample)
JP2016503799A5 (enExample)
RU2017132673A (ru) Производные собетирома
JP2015520140A5 (enExample)
JP2014507455A5 (enExample)
JP2014508811A5 (enExample)
JP2019516739A5 (enExample)
JP2016503793A5 (enExample)
JP2015516427A5 (enExample)
JP2016516043A5 (enExample)
JP2016515561A5 (enExample)
JP2015537020A5 (enExample)
JP2015504081A5 (enExample)
JP2016506960A5 (enExample)
JP2013056919A5 (enExample)
JP2013508279A5 (enExample)
JP2016503052A5 (enExample)
JP2016505614A5 (enExample)
JP2017517565A5 (enExample)
JP2011527299A5 (enExample)